Table 1 Demographic and disease characteristics of PET-CT sub-study participants
Variable | All | Rosuvastatin | Control |
|---|---|---|---|
N = 24 | N = 12 | N = 12 | |
Age, median (IQR) ** | 31.5 (23.5, 43) | 35.0 (23.5, 41.5) | 29.5 (24, 44) |
Sex – no. (%) | |||
Female | 5 (21) | 4 (33) | 1 (8) |
Male | 19 (79) | 8 (67) | 11 (92) |
Country– no. (%) | |||
Vietnamese | 13 (54) | 7 (58) | 6 (50) |
Filipino | 11 (46) | 5 (42) | 6 (50) |
Smoking status – no. (%) | |||
Never | 12 (50) | 7 (58) | 5 (42) |
Ex-Smoker | 9 (38) | 3 (25) | 6 (50) |
Current | 3 (12) | 2 (17) | 1 (8) |
Weight, mean (SD) (kg) ^ | 51.6 (9.1) | 50.9 (10.0) | 52.2 (8.4) |
BMI, mean (SD) kg/m2^ | 19.4 (2.6) | 18.9 (2.5) | 19.9 (2.7) |
Bilateral disease on CXR – no. (%) | 16 (67) | 7 (58) | 9 (75) |
Percentage of lung affected on CXR – no. (%) | |||
< 25% | 10 (42) | 6 (50) | 4 (33) |
25 – 50% | 8 (33) | 3 (25) | 5 (42) |
> 50% | 6 (25) | 3 (25) | 3 (25) |
Cavitation present on CXR – no. (%) | 16 (67) | 7 (58) | 9 (75) |
Largest cavity on CXR – no. (%) | |||
No cavity | 8 (33) | 5 (42) | 3 (25) |
≤ 4 cm | 11 (46) | 4 (33) | 7 (58) |
> 4 cm | 5 (21) | 3 (25) | 2 (17) |
Aggregate cavity on CXR – no. (%) | |||
No cavity | 8 (33) | 5 (42) | 3 (25) |
≤ 4 cm | 8 (33) | 4 (33) | 4 (33) |
5 − 8 cm | 6 (25) | 2 (17) | 4 (33) |
> 8 cm | 2 (9) | 1 (8) | 1 (9) |
WHO smear grade – no. (%) | |||
Negative | 5 (21) | 3 (25) | 2 (17) |
Scanty | 4 (16) | 3 (25) | 1 (8) |
1 + | 6 (26) | 3 (25) | 3 (25) |
2 + | 5 (21) | 2 (17) | 3 (25) |
3 + | 4 (16) | 1 (8) | 3 (25) |
Semi-quantitative TB burden on Xpert– no. (%) | |||
Negative/ Not done | 3 (13) | 0 | 3 (25) |
Low | 3 (13) | 2 (17) | 1 (8) |
Medium | 10 (42) | 6 (50) | 4 (33) |
High | 8 (33) | 4 (33) | 4 (33) |
Baseline MGIT culture positive for Mtb – no. (%) | 23 (96) | 11 (92) | 12 (100) |
Prior days of TB treatment, median (IQR) | 9 (3.5, 12.5) | 6 (2, 12) | 10 (7, 13) |
